SCHEMBL32661604

SCHEMBL32661604

CN(Cc1ccco1)c1ncnc2c1ncn2[C@@H]1O[C@H](COS(N)(=O)=O)[C@@H](O)[C@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 2/20 0.52
▸ UBA6 A0AVT1 1/20 0.52
▸ ATG7 O95352 1/20 0.52
▸ UBA7 P41226 1/20 0.52
▸ NAE1 Q13564 1/20 0.52
▸ UBA3 Q8TBC4 1/20 0.52
▸ SAE1 Q9UBE0 1/20 0.52
▸ TP53 P04637 2/20 0.50
▸ PAX8 Q06710 2/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ MITF O75030 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ TRPM2 O94759 1/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.48
▸ ADORA2A P29274 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32662695 0.88 SLC29A1 (0.60) SLC29A1UBA6ATG7UBA7NAE1
SCHEMBL32662391 0.82 RXFP1 (0.60) UBA6ATG7UBA7NAE1UBA3
SCHEMBL32662533 0.82 ADORA3 (0.75) SLC29A1UBA6ATG7UBA7NAE1
SCHEMBL32661821 0.82 KDM4E (0.63) UBA6ATG7UBA7NAE1UBA3
SCHEMBL32661691 0.81 LARS1 (0.57) UBA6ATG7UBA7NAE1UBA3
SCHEMBL1797355 0.81 UBA6 (0.57) UBA6ATG7UBA7NAE1UBA3
SCHEMBL32661820 0.78 RXFP1 (0.61) CA1CA2CA4CA9RXFP1
SCHEMBL5321913 0.78 ATG7 (0.63) UBA6ATG7UBA7NAE1UBA3
SCHEMBL1796966 0.78 ATG7 (0.63) UBA6ATG7UBA7NAE1UBA3
SCHEMBL32661844 0.77 RXFP1 (0.60) CA1CA2CA4CA9RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) 2026-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015592-A1 NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF NAE1, NEDD8, UBA3 SLC29A1 295/4885UBA6 153/4885ATG7 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback